Menu
Menu
Alembic Pharmaceuticals has secured USFDA approval for its generic version of Brexpiprazole Tablets, a treatment for major depressive disorder and schizophrenia. This approval opens the door to a $2 billion market, providing a more affordable option for patients while strengthening Alembic’s position in the generics sector.
Lupin has acquired the Huminsulin range of insulin products from Eli Lilly in India, significantly expanding its diabetes portfolio. This strategic acquisition will help provide millions of patients with access to affordable, high-quality insulin options for better diabetes management.
Glenmark Pharmaceuticals has launched its Lacosamide Oral Solution, a bioequivalent to Vimpat® Oral Solution, offering a more affordable treatment option for partial-onset seizures. This new product enhances access to epilepsy care, with the same therapeutic efficacy as the branded version, making it a valuable option for patients and healthcare providers.
Glenmark Pharmaceuticals has launched its Travoprost Ophthalmic Solution USP, 0.004%, a generic alternative to Travatan Z, designed to help manage glaucoma and ocular hypertension. This cost-effective, bioequivalent solution offers the same therapeutic benefits, providing patients with an affordable option for controlling intraocular pressure and preventing optic nerve damage.
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has secured EU GMP certification for its biosimilars manufacturing facility, a key milestone in its global expansion. This certification positions Aurobindo to bring high-quality biosimilars to the European market, with three products currently under review for approval.
Alembic Pharmaceuticals has received USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, a key treatment for hypertension. This approval allows Alembic to offer an affordable alternative to patients, enhancing access to essential cardiovascular care while expanding its presence in the U.S. generic drug market.
Zydus Lifesciences has achieved a major milestone with USFDA approval for Amantadine extended-release capsules, aimed at treating dyskinesia in Parkinson’s disease patients. The company has also received tentative approval for Gocovri capsules, promising more affordable treatment options. Discover how these approvals could enhance access to essential Parkinson's disease therapies.
Dive into the realm of affordable healthcare solutions with Glenmark's Generic Esomeprazole Magnesium, offering effective relief from acid-related discomforts at a fraction of the cost of branded alternatives. Explore the world of generic medications with Glenmark's Esomeprazole Magnesium, a trusted choice for individuals seeking relief from conditions triggered by excessive stomach acid production, now accessible with USFDA approval. Unlock the potential for cost-effective treatment options with Glenmark's Generic Esomeprazole Magnesium, designed to provide the same therapeutic benefits as branded medications, ensuring quality care for acid-related ailments. Embrace the promise of affordable healthcare with Glenmark's Generic Esomeprazole Magnesium, a testament to the company's commitment to delivering accessible medication options without compromising on quality or efficacy. Step into a realm of accessible relief with Glenmark's Esomeprazole Magnesium, FDA-approved and ready to address the discomforts associated with conditions stemming from excessive acid production in the stomach.